[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Duke et al., 1997 - Google Patents

CD95 (Fas) Ligand: A Mediator of Cytotoxic T Lymphocyte-Mediated Apoptosis and Immune Privilege

Duke et al., 1997

Document ID
6336174021632745842
Author
Duke R
Nash P
Schleicher M
Richards C
Moore J
Newell E
Franzusoff A
Bellgrau D
Publication year
Publication venue
Programmed Cell Death

External Links

Snippet

Abstract CD95 (Fas/APO-1) is a 45 kD cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (Nagata and Golstein 1995; Itoh et al. 1991; Oehm et al. 1992; Watanabe-Fukunaga et al. 1992a; Smith et al. 1994). Although CD95 is expressed in …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
US11981743B2 (en) Monoclonal antibody and a method thereof
Rothstein et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models
Caldwell et al. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases
Brem-Exner et al. Macrophages driven to a novel state of activation have anti-inflammatory properties in mice
WO2003083069A2 (en) Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb
Hishii et al. Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes
Martinez et al. CD30 EXPRESSION IDENTIFIES A FUNCTIONAL ALLOREACTIVE HUMAN T-LYMPHOCYTE SUBSET1
US6994976B1 (en) Tr3-specific binding agents and methods for their use
Krams et al. Apoptosis as a mechanism of tissue injury in liver allograft rejection
Bueno et al. The role of CD8+ T cells during allograft rejection
Donnelly et al. Human natural killer cells account for non-MHC class I-restricted cytolysis of porcine cells
Eischen et al. Role for NK-cell-associated Fas ligand in cell-mediated cytotoxicity and apoptosis
Nakazawa et al. Later development of Fas ligand‐mediated cytotoxicity as compared with granule‐mediated cytotoxicity during the maturation of natural killer cells
Gelfanov et al. Activated alpha beta-CD8+, but not alpha alpha-CD8+, TCR-alpha beta+ murine intestinal intraepithelial lymphocytes can mediate perforin-based cytotoxicity, whereas both subsets are active in Fas-based cytotoxicity.
Duke et al. CD95 (Fas) Ligand: A Mediator of Cytotoxic T Lymphocyte-Mediated Apoptosis and Immune Privilege
Moore et al. 1. CD95 AND ITS LIGAND: DOWN-REGULATION OF IMMUNE RESPONSES
Sen Targeting Siglecs on Recipient Antigenpresenting Cells With Sialic Acid-Modified Alloantigen to Promote Transplantation Tolerance
Maxwell The role of costimulation and adjuvants in the development of T cell effector and memory responses
Allison et al. Can expression of CD95 (Fas/APO-1) ligand on grafts or tumor cells prevent their rejection?
Villegas The role of costimulatory molecules during protective and pathogenic immune responses following infection with Toxoplasma gondii
Jiang Effector cells and mechanisms of the GVL effect
AU2003243138A1 (en) Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb
Haeryfar Evidence of fundamental differences between Thy-1-and T cell receptor-associated pathways of T cell activation.
Juvet Regulation of Fas-deficient Lymphoproliferative Double Negative T Cells by Interferon Gamma and the Fc Receptor Gamma Chain
Marks Characterization of perforin and Fas ligand effector and regulatory T cell functions in allogeneic bone marrow transplantation